Product Information for the Patient
Vokanamet 50 mg/850 mg Film-Coated Tablets
Vokanamet 50 mg/1.000 mg Film-Coated Tablets
Vokanamet 150 mg/850 mg Film-Coated Tablets
Vokanamet 150 mg/1.000 mg Film-Coated Tablets
canagliflozina/hidrocloruro de metformina
Read this entire product information carefully before starting to take this medicine, as it contains important information for you.
Vokanamet contains two distinct active principles, canagliflozina and metformina. These are two medications that act together through different pathways to decrease blood glucose (sugar) levels and may help prevent heart disease in adults with type 2 diabetes.
This medication is administered alone or in combination with other medications that you may already be taking to treat your type 2 diabetes (such as insulin, a DPP-4 inhibitor [such as sitagliptina, saxagliptina, or linagliptina], a sulfonylurea [such as glimepiride or glipizide], or pioglitazona) that decrease blood sugar levels. It is possible that you are already taking one or more of these medications to treat your type 2 diabetes. Vokanamet is used when your blood sugar levels cannot be controlled adequately with metformina alone or in combination with other diabetes medications. If you are already taking canagliflozina and metformina as separate tablets, Vokanamet may replace them in a single tablet.
It is essential that you do not stop following the dietary and exercise recommendations provided by your doctor or nurse.
What is type 2 diabetes?
Type 2 diabetes is a disorder in which the body does not produce enough insulin and the insulin that is produced does not function as well as it should. It may also be that your body produces too much sugar. When this occurs, sugar (glucose) accumulates in the blood. This can produce serious medical diseases, such as heart disease, kidney disease, blindness, and amputations.
Do not take Vokanamet
Warnings and precautions
Risk of lactic acidosis
Vokanamet may cause a very rare but serious side effect called lactic acidosis, especially if your kidneys do not work properly. The risk of developing lactic acidosis is also increased with uncontrolled diabetes, severe infections, prolonged fasting or drinking alcohol, dehydration (see below for more information), liver problems, and any medical condition in which a part of the body has a reduced oxygen supply (such as acute and severe heart disease)
If any of the above applies to you, consult your doctor for further instructions
Stop taking Vokanamet temporarily if you have a condition that may be associated with dehydration(significant loss of body fluids), such as intense vomiting, diarrhea, fever, exposure to heat, or if you drink less fluid than normal. Consult your doctor for further instructions
Stop taking Vokanamet and talk to a doctor or go to the nearest hospital immediately if you experience any of the symptoms that cause lactic acidosis,sincethis condition can lead to coma
The symptoms of lactic acidosis include:
Lactic acidosis is a medical emergency and should be treated in a hospital
Consult your doctor, pharmacist, or nurse before starting to take Vokanamet and during treatment:
Kidney function
Your kidneys will be reviewed through a blood test before starting to take Vokanamet. During treatment with Vokanamet, your doctor will check your kidney function at least once a year or more frequently if you are an older person and/or if your kidney function is worsening
Surgery
If you need to undergo major surgery, stop taking Vokanamet while the procedure is being performed and for a period after. Your doctor will decide when to interrupt Vokanamet treatment and when to restart it
Your doctor will decide if you need any other treatment to control your blood sugar levels while you stop taking Vokanamet. It is essential to follow your doctor's instructions exactly
Blood sugar in urine
Due to the way canagliflozina works, your urine will test positive for sugar (glucose) while you are taking this medicine
Children and adolescents
Vokanamet is not recommended for children or adolescents under 18 years of age, as there is no data available for these patients
Other medicines and Vokanamet
If you need to receive an injection of a contrast medium containing iodine, for example, in the context of an X-ray or examination, stop taking Vokanamet before the injection or at the time of the injection. Your doctor will decide when to interrupt Vokanamet treatment and when to restart it
Inform your doctor if you are taking, have taken recently, or may need to take any other medicine. You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dose of Vokanamet. It is especially important to mention the following:
Taking Vokanamet with alcohol
Avoid excessive alcohol consumption while taking Vokanamet, as this may increase the risk of lactic acidosis (see section "Warnings and precautions")
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using or continuing to use this medicine
Canagliflozina, one of the components of Vokanamet, should not be used during pregnancy. Consult your doctor for the best way to control your blood sugar levels without Vokanamet as soon as you know you are pregnant
You should not take this medicine if you are breastfeeding. Consult your doctor if you need to stop taking this medicine or if you need to stop breastfeeding
Driving and using machines
The influence of Vokanamet on your ability to drive, ride a bike, and use tools or machines is negligible or insignificant. However, dizziness or lightheadedness may affect your ability to drive, ride a bike, or use tools or machines
Taking Vokanamet with other diabetes medicines called sulfonylureas (such as glimepiride or glipizide) or insulin may increase the risk of low blood sugar levels (hypoglycemia). Symptoms include blurred vision, tingling in the lips, tremors, sweating, paleness, mood changes, anxiety, or confusion. This may affect your ability to drive, ride a bike, and use tools or machines. Inform your doctor as soon as possible if you experience any symptoms of low blood sugar
Vokanamet contains sodium
This medicine contains less than 1 mmol (23 mg) of sodium per tablet; it is essentially "sodium-free"
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
How much to take
How to take this medication
Your doctor may prescribe Vokanamet with another medication to reduce glucose. Remember to take all medications as directed by your doctor to achieve the best results for your health.
Diet and exercise
To help control your diabetes, you should also follow the dietary and exercise advice from your doctor, pharmacist, or nurse. In particular, if you are following a weight-control diabetic diet, you should continue it while taking this medication.
If you take more Vokanamet than you should
Since Vokanamet contains metformin, if you take more medication than you should, you may develop lactic acidosis. If this happens to you, you may need immediate hospital treatment, as lactic acidosis can cause coma. Symptoms of lactic acidosis include vomiting, stomach pain, muscle cramps, a general feeling of discomfort with intense fatigue or difficulty breathing. Other symptoms are reduced body temperature and heart rate. Stop taking this medication immediately and contact a doctor or the nearest hospital (see section 2) right away. Bring the medication packaging with you.
If you forget to take Vokanamet
If you interrupt treatment with Vokanamet
Your blood sugar concentration may increase if you stop taking this medication. Do not stop taking this medication without first talking to your doctor.
If you have any other questions about using this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Stop taking Vokanamet and talk to your doctor or go to the nearest hospital immediately if you notice any of the following serious side effects:
Severe allergic reaction (rare, may affect up to 1 in 1,000 people)
Possible symptoms of a severe allergic reaction may include:
Lactic acidosis (very rare, may affect up to 1 in 10,000 people)
Vokanamet may cause a very rare but serious side effect (may affect up to 1 user in 10,000), called lactic acidosis (see section “Warnings and precautions”). If this happens to you,you must stop taking Vokanamet and talk to your doctor or go to the nearest hospitalimmediately, as lactic acidosis can lead to coma.
Diabetic ketoacidosis (rare, may affect up to 1 in 1,000 people)
These are the symptoms of diabetic ketoacidosis (see also section 2):
This can occur regardless of your blood glucose levels. Your doctor may decide to temporarily or permanently interrupt treatment with Vokanamet.
Dehydration (infrequent, may affect up to 1 in 100 people)
Possible symptoms of dehydration are:
Inform your doctor as soon as possible if you notice any of the following side effects:
Hypoglycemia (very common, may affect more than 1 in 10 people)
Possible symptoms of low blood sugar are:
Your doctor will explain how to treat low blood sugar and what to do if you experience any of the above symptoms.
Urinary tract infections (frequent, may affect up to 1 in 10 people)
Although infrequent, if you notice blood in your urine, inform your doctor immediately.
Other side effects of treatment with canagliflozin alone:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Infrequent (may affect up to 1 in 100 people)
Frequency not known (cannot be estimated from available data)
Side effects during treatment with metformin alone that were not described for canagliflozin:
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directlythrough the national notification system included in theAppendix V.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the bottle and the box after CAD. The expiration date is the last day of the month indicated.
Do not store above 86°F (30° C).
Do not use Vokanamet if you observe visible signs of deterioration or manipulation.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medication that you no longer need. This will help protect the environment.
Composition of Vokanamet
Appearance of Vokanamet and packaging contents
Vokanamet is available in HDPE bottles with child-resistant closures. The packaging sizes are boxes of 20 and 60 tablets, and multiple packs of 180 tablets (3 bottles containing 60 tablets each).
Only some packaging sizes may be marketed.
Marketing Authorization Holder
Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium
Responsible for manufacturing
Janssen-Cilag SpA
Via C. Janssen
Borgo San Michele
04100 Latina
Italy
For more information about this medicine, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien Menarini Benelux NV/SA Tel/Tel: +32 (0)2 721 4545 | Lietuva UAB"JOHNSON & JOHNSON" Tel: +370 5 278 68 88 |
Luxembourg/Luxemburg Menarini Benelux NV/SA Tél/Tel: +32 (0)2 721 4545 | |
Ceská republika Berlin-Chemie/A.Menarini Ceska republika s.r.o. Tel: +420 267 199 333 office@berlin-chemie.cz | Magyarország Janssen‑Cilag Kft. Tel.: +36 1 884 2858 |
Danmark Berlin-Chemie AG Tlf: +45 78 71 31 21 | Malta AM MANGION LTD. Tel: +356 2397 6333 |
Deutschland Janssen‑Cilag GmbH Tel: +49 2137 955‑955 | Nederland Menarini Benelux NV/SA Tel: +32 (0)2 721 4545 |
Eesti UAB "JOHNSON & JOHNSON" Eesti filiaal Tel: +372 617 7410 | Norge Berlin-ChemieAG Tlf: +45 78 71 31 21 |
Ελλ?δα MENARINI HELLAS AE Tηλ: +30 210 8316111-13 | Österreich A. Menarini Pharma GmbH Tel: +43 1 879 95 85-0 |
España Laboratorios Menarini, S.A. Tel: +34 93 462 88 00 | Polska Berlin-Chemie/Menarini Polska Sp. z o.o. Tel.: +48 22 566 21 00 |
France MENARINI France Tél: +33 (0)1 45 60 77 20 | Portugal A. Menarini Portugal – Farmacêutica, S.A. Tel: +351 210 935 500 |
Hrvatska Johnson & Johnson S.E. d.o.o. Tel: +385 1 6610 700 | România Johnson & Johnson România SRL Tel: +40 21 207 1800 |
Ireland A. Menarini Pharmaceuticals Ireland Ltd Tel: +353 1 284 6744 | Slovenija Johnson & Johnson d.o.o. Tel: +386 1 401 18 00 |
Ísland Janssen‑Cilag AB c/o Vistor hf. Sími: +354 535 7000 | Slovenská republika Berlin-Chemie / A. Menarini Distribution Slovakia s.r.o Tel: +421 2544 30730 |
Italia Laboratori Guidotti S.p.A. Tel: +39 050 971011 | Suomi/Finland Berlin-Chemie/A. Menarini Suomi Oy Puh/Tel: +358 403 000 760 |
Κ?προς MENARINI HELLAS AE Τηλ: +30 210 8316111-13 | Sverige Berlin-ChemieAG Tfn: +45 78 71 31 21 |
Latvija UAB "JOHNSON & JOHNSON" filiale Latvija Tel: +371 678 93561 | United Kingdom (Northern Ireland) A. Menarini Farmaceutica Internazionale S.R.L. Tel: +44 (0)1628 856400 |
Last revision date of this leaflet: June 2023.
Other sources of information
The detailed information on this medicine is available on the website of the European Medicines Agency:http://www.ema.europa.euand on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/).
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.